September, 2023
InSysBio announces its participation in SITC's 38th Annual Meeting (the Society for Immunotherapy of Cancer) which is to be held on November 1 - 5, 2023 at San Diego Convention Center, San Diego, California or Virtual. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1133 and 6 posters in frames of the Meeting, namely:
338 "Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies via mathematical modeling" by Oleg Demin Jr1, Galina Kolesova2, Natalia Ramos Hernandez3, Thomas Faitg3, Stefan Zajic3, Lourdes Cucurull-Sanchez4
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
354 "Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling" by Oleg Demin Jr1, Galina Kolesova2, Stefan Zajic3, Lourdes Cucurull-Sanchez4
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
480 "Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses" by Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, N
1167 "Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling" by Oleg Demin Jr, Dmitry Shchelokov
1280 "Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data" by Oleg Demin2, Sergey Smirnov1, Alexandra Diakonova1, Anna Roskoshnaya1, Gaurav Bajaj3, Homer Adams III3, Manish Gupta3, Craig Thalhauser3
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro N
Check out our Booth #1133 at SITC 2023!
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
| ||
Thank you for your message! We will get back to you shortly.
